Lead Product(s) : Relmapirazin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Runway Growth Capital LLC
Deal Size : Undisclosed
Deal Type : Financing
Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital
Details : This financing provides the enhanced financial flexibility to develop the gene and cell therapies, including CD123 CAR-T, in fully integrated cell processing facility in Worcester, Mass. that has capacity to launch at commercial scale.
Product Name : MB-102
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 03, 2022
Lead Product(s) : Relmapirazin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Runway Growth Capital LLC
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Relmapirazin,Decitabine,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 portion of the trial will determine the maximum tolerated dose of MB-102 for the Phase 2 portion of the trial. Safety will be assessed at each dose level before proceeding to the next.
Product Name : MB-102
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 10, 2020
Lead Product(s) : Relmapirazin,Decitabine,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
